Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway.
Saved in:
| Title: | Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway. |
|---|---|
| Authors: | Hsu, Man-Chen1, Chang, Ru-Wen2, Wang, Mu-Chun3, Chen, Chia-Hui1, Chen, Wen-Hua1, Lee, Tzong-Shyuan1 ntutslee@ntu.edu.tw, Wang, Chih-Hsien2 wchemail@ntu.edu.tw |
| Source: | Journal of Food & Drug Analysis. 2025, Vol. 33 Issue 4, p421-433. 13p. |
| Database: | Academic Search Ultimate |
| ISSN: | 10219498 |
|---|---|
| DOI: | 10.38212/2224-6614.3563 |
